Cargando…

Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans

OBJECTIVE: Proton pump inhibitors (PPIs) are widely used, and their use is associated with increased risk of adverse events. However, whether PPI use is associated with excess risk of death is unknown. We aimed to examine the association between PPI use and risk of all-cause mortality. DESIGN: Longi...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Yan, Bowe, Benjamin, Li, Tingting, Xian, Hong, Yan, Yan, Al-Aly, Ziyad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Open 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642790/
https://www.ncbi.nlm.nih.gov/pubmed/28676480
http://dx.doi.org/10.1136/bmjopen-2016-015735
_version_ 1783271429414846464
author Xie, Yan
Bowe, Benjamin
Li, Tingting
Xian, Hong
Yan, Yan
Al-Aly, Ziyad
author_facet Xie, Yan
Bowe, Benjamin
Li, Tingting
Xian, Hong
Yan, Yan
Al-Aly, Ziyad
author_sort Xie, Yan
collection PubMed
description OBJECTIVE: Proton pump inhibitors (PPIs) are widely used, and their use is associated with increased risk of adverse events. However, whether PPI use is associated with excess risk of death is unknown. We aimed to examine the association between PPI use and risk of all-cause mortality. DESIGN: Longitudinal observational cohort study. SETTING: US Department of Veterans Affairs. PARTICIPANTS: Primary cohort of new users of PPI or histamine H2 receptor antagonists (H2 blockers) (n=349 312); additional cohorts included PPI versus no PPI (n=3 288 092) and PPI versus no PPI and no H2 blockers (n=2 887 030). MAIN OUTCOME MEASURES: Risk of death. RESULTS: Over a median follow-up of 5.71 years (IQR 5.11–6.37), PPI use was associated with increased risk of death compared with H2 blockers use (HR 1.25, CI 1.23 to 1.28). Risk of death associated with PPI use was higher in analyses adjusted for high-dimensional propensity score (HR 1.16, CI 1.13 to 1.18), in two-stage residual inclusion estimation (HR 1.21, CI 1.16 to 1.26) and in 1:1 time-dependent propensity score-matched cohort (HR 1.34, CI 1.29 to 1.39). The risk of death was increased when considering PPI use versus no PPI (HR 1.15, CI 1.14 to 1.15), and PPI use versus no PPI and no H2 blockers (HR 1.23, CI 1.22 to 1.24). Risk of death associated with PPI use was increased among participants without gastrointestinal conditions: PPI versus H2 blockers (HR 1.24, CI 1.21 to 1.27), PPI use versus no PPI (HR 1.19, CI 1.18 to 1.20) and PPI use versus no PPI and no H2 blockers (HR 1.22, CI 1.21 to 1.23). Among new PPI users, there was a graded association between the duration of exposure and the risk of death. CONCLUSIONS: The results suggest excess risk of death among PPI users; risk is also increased among those without gastrointestinal conditions and with prolonged duration of use. Limiting PPI use and duration to instances where it is medically indicated may be warranted.
format Online
Article
Text
id pubmed-5642790
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Open
record_format MEDLINE/PubMed
spelling pubmed-56427902017-10-25 Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans Xie, Yan Bowe, Benjamin Li, Tingting Xian, Hong Yan, Yan Al-Aly, Ziyad BMJ Open Public Health OBJECTIVE: Proton pump inhibitors (PPIs) are widely used, and their use is associated with increased risk of adverse events. However, whether PPI use is associated with excess risk of death is unknown. We aimed to examine the association between PPI use and risk of all-cause mortality. DESIGN: Longitudinal observational cohort study. SETTING: US Department of Veterans Affairs. PARTICIPANTS: Primary cohort of new users of PPI or histamine H2 receptor antagonists (H2 blockers) (n=349 312); additional cohorts included PPI versus no PPI (n=3 288 092) and PPI versus no PPI and no H2 blockers (n=2 887 030). MAIN OUTCOME MEASURES: Risk of death. RESULTS: Over a median follow-up of 5.71 years (IQR 5.11–6.37), PPI use was associated with increased risk of death compared with H2 blockers use (HR 1.25, CI 1.23 to 1.28). Risk of death associated with PPI use was higher in analyses adjusted for high-dimensional propensity score (HR 1.16, CI 1.13 to 1.18), in two-stage residual inclusion estimation (HR 1.21, CI 1.16 to 1.26) and in 1:1 time-dependent propensity score-matched cohort (HR 1.34, CI 1.29 to 1.39). The risk of death was increased when considering PPI use versus no PPI (HR 1.15, CI 1.14 to 1.15), and PPI use versus no PPI and no H2 blockers (HR 1.23, CI 1.22 to 1.24). Risk of death associated with PPI use was increased among participants without gastrointestinal conditions: PPI versus H2 blockers (HR 1.24, CI 1.21 to 1.27), PPI use versus no PPI (HR 1.19, CI 1.18 to 1.20) and PPI use versus no PPI and no H2 blockers (HR 1.22, CI 1.21 to 1.23). Among new PPI users, there was a graded association between the duration of exposure and the risk of death. CONCLUSIONS: The results suggest excess risk of death among PPI users; risk is also increased among those without gastrointestinal conditions and with prolonged duration of use. Limiting PPI use and duration to instances where it is medically indicated may be warranted. BMJ Open 2017-07-04 /pmc/articles/PMC5642790/ /pubmed/28676480 http://dx.doi.org/10.1136/bmjopen-2016-015735 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Public Health
Xie, Yan
Bowe, Benjamin
Li, Tingting
Xian, Hong
Yan, Yan
Al-Aly, Ziyad
Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans
title Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans
title_full Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans
title_fullStr Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans
title_full_unstemmed Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans
title_short Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans
title_sort risk of death among users of proton pump inhibitors: a longitudinal observational cohort study of united states veterans
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642790/
https://www.ncbi.nlm.nih.gov/pubmed/28676480
http://dx.doi.org/10.1136/bmjopen-2016-015735
work_keys_str_mv AT xieyan riskofdeathamongusersofprotonpumpinhibitorsalongitudinalobservationalcohortstudyofunitedstatesveterans
AT bowebenjamin riskofdeathamongusersofprotonpumpinhibitorsalongitudinalobservationalcohortstudyofunitedstatesveterans
AT litingting riskofdeathamongusersofprotonpumpinhibitorsalongitudinalobservationalcohortstudyofunitedstatesveterans
AT xianhong riskofdeathamongusersofprotonpumpinhibitorsalongitudinalobservationalcohortstudyofunitedstatesveterans
AT yanyan riskofdeathamongusersofprotonpumpinhibitorsalongitudinalobservationalcohortstudyofunitedstatesveterans
AT alalyziyad riskofdeathamongusersofprotonpumpinhibitorsalongitudinalobservationalcohortstudyofunitedstatesveterans